PHARMING GROUP news, videos and press releases
For more news please use our advanced search feature.
PHARMING GROUP - More news...
PHARMING GROUP - More news...
- Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
- Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
- Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
- Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
- Pharming Group to participate in March investor conference
- Pharming Group to report fourth quarter and full year 2024 financial results on March 13
- Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
- Pharming Group to participate in February investor conference
- Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
- Pharming Group to convene Extraordinary General Meeting of Shareholders
- Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
- Pharming announces public cash offer to the shareholders of Abliva AB
- Pharming announces positive topline data in pediatric clinical trial of leniolisib
- Pharming Group to participate in November investor conference
- Pharming Group reports third quarter 2024 financial results and provides business update
- Pharming Group to report third quarter 2024 financial results on October 24
- Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
- Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
- Pharming Group to participate in September investor conferences
- Pharming Group reports second quarter and first half 2024 financial results and provides business update
- Pharming Group to report second quarter and first half 2024 financial results on August 1
- Pharming Group to participate in June investor conferences
- Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
- Pharming Group to participate in May investor conference
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
- Pharming Group reports first quarter 2024 financial results and provides business update
- Pharming Group to report first quarter 2024 financial results on May 8
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
